Boston Scientific Expects MADIT-CRT Results To Energize CRM Sales
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific is preparing a major sales and marketing effort to support an expanded indication for its cardiac resynchronization therapy devices based on the results of the MADIT-CRT trial
You may also be interested in...
Boston Scientific Gains Expanded Indication For CRT-D Devices
Boston Scientific hopes its newfound ability to legally market its cardiac resynchronization therapy defibrillators for use in a broader heart failure population will help its efforts to regain lost market share in the sector
Boston Scientific Gains Expanded Indication For CRT-D Devices
Boston Scientific hopes its newfound ability to legally market its cardiac resynchronization therapy defibrillators for use in a broader heart failure population will help its efforts to regain lost market share in the sector
FDA Panel Endorses Expanded Approval For Boston Scientific CRT-Ds
Boston Scientific's cardiac resynchronization therapy defibrillators (CRT-Ds) should be approved for use in some healthier heart failure patients, though not quite as many as the company initially proposed, an FDA advisory panel said March 18